A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6-VALENT OSPA-BASED LYME DISEASE CACCINE IN HEALTHY PARTICIPANTS 5 YEARS OLD AND OLDER
- Registry ID
- C4601003
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- PFIZER CANADA ULC
- Start date
- 2024-08-21
- Last update
- 2023-06-01
Conditions
Related clinical trials
- A PHASE 2, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1982, AN MRNA VACCINE TO PREVENT LYME DISEASE IN HEALTHY ADULT PARTICIPANTS (18 TO 70 YEARS OF AGE)
- A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF FIFTH DOSE OF 6-VALENT OSPA-BASED LYME DIDEASE VACCINE, VLA15, IN HEALTHY PARTICIPANTS 7 YEARS OF AGE
View on source registry